Cervical Cancer is malignant disease arising from the cervix, the lower portion of the uterus that connects with the vagina. The majority of cervical cancers are associated with persistent infection by high-risk human papillomavirus types, particularly HPV types with oncogenic potential. The main histological categories are squamous cell carcinoma and adenocarcinoma, with smaller numbers of other tumour types. Cervical carcinogenesis generally occurs over years through persistent viral infection followed by cellular changes that can progress from precancerous lesions to invasive malignancy. This relatively prolonged natural history creates substantial opportunities for prevention through HPV vaccination and screening before invasive cancer develops.
Human papillomavirus infection is extremely common, and most infections are transiently cleared by the immune system. Persistent infection with high-risk HPV is the critical causal factor for the great majority of Cervical Cancer, although cofactors influence whether persistence leads to progression. Smoking, immunosuppression, HIV infection and certain reproductive or sexual health factors can increase risk. The causal role of HPV distinguishes Cervical Cancer from many other cancers in which no single infectious agent accounts for most cases. Prevention therefore includes vaccination against oncogenic HPV types and screening designed to identify persistent infection or cellular abnormalities before invasive disease develops.
Early Cervical Cancer may produce no symptoms. When symptoms occur, they can include abnormal vaginal bleeding, bleeding after sexual intercourse, bleeding between periods, unusual vaginal discharge or pelvic pain. Advanced disease can cause pelvic pain, urinary or bowel symptoms, leg swelling or other manifestations associated with local invasion or distant spread. These symptoms can have many non-cancerous causes, but persistent or unusual bleeding warrants clinical assessment. Symptom absence does not exclude precancerous cervical changes, which is why screening remains important even when a person feels completely well.
Cervical screening does not generally search directly for invasive cancer; it aims to identify high-risk HPV infection and/or abnormal cervical cells that indicate increased risk of progression. HPV testing has become a central screening method in many healthcare systems because persistent high-risk HPV is closely associated with the development of cervical precancer. Abnormal screening results can lead to further assessment, such as colposcopy and biopsy. Screening programmes differ in age ranges, intervals and test pathways according to national policy and evidence. Vaccination does not eliminate the need for screening because current vaccines do not protect against every oncogenic HPV type and vaccination coverage or previous exposure may vary.
Histopathology distinguishes precancerous lesions from invasive cancer and identifies the tumour type. Colposcopy allows magnified examination of the cervix and targeted biopsy of suspicious areas. Once invasive cancer is diagnosed, staging determines the extent of local, regional and distant disease. MRI can be particularly useful for assessing local tumour extent, while CT or PET-based imaging may be used to evaluate lymph nodes and distant disease in appropriate settings. Staging has traditionally been clinical but modern systems incorporate imaging and pathological information where available. Tumour size, parametrial involvement, nodal disease and metastasis are particularly important determinants of management.
Treatment depends on stage, tumour size, histology, fertility considerations and overall clinical circumstances. Very early disease may be treated with local excision or other fertility-sparing procedures in carefully selected patients. More locally advanced disease is commonly treated with chemoradiotherapy, frequently using a platinum-based radiosensitising drug, followed by brachytherapy. Surgery can be used for selected early-stage cancers. Advanced or recurrent disease may require systemic therapy, including chemotherapy, immune checkpoint inhibition or targeted approaches in appropriate molecular and clinical settings. Treatment aims differ between curative local therapy and systemic management of metastatic disease.
Cervical Cancer is unusual among common cancers because a highly effective causal-prevention strategy exists. HPV vaccination reduces infection with targeted oncogenic HPV types and substantially reduces the risk of HPV-associated precancer and cancer, particularly when administered before exposure. Screening further reduces mortality by detecting precancerous changes or early cancer. However, vaccine effectiveness does not mean every vaccinated person has complete protection, and screening remains necessary under current programmes. Inequalities in vaccination, screening access, follow-up and treatment can produce substantial differences in disease burden between populations.
Prognosis is strongly related to stage at diagnosis, with early-stage disease generally more amenable to curative treatment than advanced disease. A common misconception is that HPV infection is equivalent to cancer; most HPV infections do not progress to malignancy. Another is that a normal screening result guarantees permanent absence of future disease; screening reduces risk but cannot eliminate it. Cervical Cancer prevention therefore depends on vaccination, appropriate screening, timely investigation of abnormal results and effective treatment of identified disease. Continued research focuses on improving vaccination coverage, screening technologies, treatment of advanced disease and strategies for reducing global disparities in prevention and cancer care.
